Raffles Medical Group's stock is soaring 3.26% in intraday trading on Tuesday, following a positive research report from RHB Research. The healthcare provider's shares have gained traction after analyst Shekhar Jaiswal upgraded the stock to "buy" from "neutral" and raised the target price to S$1.08 from S$0.95.
The upgrade comes as RHB Research identifies Raffles Medical as a likely defensive option in the current volatile market environment. Jaiswal notes that the company's healthcare business has normalized, with patient load returning to pre-pandemic levels. Moreover, the analyst expects the hospital business to see higher revenue as its China-based hospitals, previously affected by pandemic restrictions, begin to scale up operations.
Investors appear to be responding positively to the improved outlook and the defensive nature of Raffles Medical's earnings amid macroeconomic uncertainties. The stock's strong performance today reflects growing confidence in the company's ability to navigate the current market conditions and potentially outperform in the healthcare sector.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。